Common use of DIRECTORS’ CONFIRMATION Clause in Contracts

DIRECTORS’ CONFIRMATION. The Directors (including the independent non-executive Directors) are of the view that the terms of the Promotional Services Agreement (2022 Renewal) (including the annual cap thereunder) are fair and reasonable, and that the transactions contemplated under the above- mentioned agreement are in the ordinary and usual course of business of the Company, on normal commercial terms and in the interests of the Company and the Shareholders as a whole. As at the date of this announcement, as each of Xx. Xxxx Xxxx, Xx. Xxxxxx Xx, Xx. Xxxxxxx Xxxx, Xx. Xxxxx Xxx and Xx. Xxxxx Xxx holds various positions with Fosun Pharma and/or their respective subsidiaries, each of them has abstained from voting on the Board resolutions approving the Promotional Services Agreement (2022 Renewal). Save for the above, to the best knowledge, information and belief of the Directors after having made all reasonable enquiries, no other Director has a material interest in the Promotional Services Agreement (2022 Renewal), and no other Director has abstained from voting on the relevant Board resolution approving the Promotional Services Agreement (2022 Renewal).

DIRECTORS’ CONFIRMATION. The Directors (including the independent non-executive Directors) are of the view that the terms of the Promotional Services Agreement (2022 Renewalas supplemented) (including the revised annual cap thereundercaps) are fair and reasonable, and that the transactions contemplated under the above- mentioned agreement thereunder are in the ordinary and usual course of business of the Company, on normal commercial terms and in the interests of the Company and the Shareholders as a whole. As at the date of this announcement, as each of Xx. Xxxx Xxxx, Xx. Xxxxxx Xx, Xx. Xxxxxxx Xxxx, Xx. Xxxxx Xxx and Xx. Xxxxx Xxx holds various positions with Fosun Pharma and/or their respective its subsidiaries, each of them has abstained from voting on the Board resolutions resolution approving the revised annual caps under the Promotional Services Agreement (2022 Renewalas supplemented). Save for the above, to the best knowledge, information and belief of the Directors after having made all reasonable enquiries, no other Director has a material interest in the Promotional Promotion Services Agreement (2022 Renewalas supplemented), and no other Director has abstained from voting on the relevant Board resolution approving the Promotional Services Agreement (2022 Renewal)revised annual caps thereunder.

DIRECTORS’ CONFIRMATION. The Directors (including the independent non-executive Directors) are of the view that the terms of the Promotional Financial Services Agreement (2022 Renewal) (including and the relevant proposed annual cap thereunder) caps in respect of each of the Services are fair and reasonable, and that the transactions contemplated under the above- mentioned agreement Financial Services Agreement are in the ordinary and usual course of business of the Company, on normal commercial terms and in the interests of the Company and the Shareholders as a whole. As at the date of this announcement, as each of Xx. Xxxx Xxxx, Xx. Xxxxxx Xx, Xx. Xxxxxxx Xxxx, Xx. Xxxxx Xxxxxx Xxx and Xx. Xxxxx Xxx holds various positions with Fosun Pharma High Tech and/or their respective its subsidiaries, each of them has abstained from voting on the Board resolutions approving the Promotional Financial Services Agreement (2022 Renewal)and the transactions contemplated thereunder. Save for the above, to the best knowledge, information and belief of the Directors after having made all reasonable enquiries, no other Director has a material interest in the Promotional Financial Services Agreement (2022 Renewal)Agreement, and no other Director has abstained from voting on the relevant Board resolution resolutions approving the Promotional Financial Services Agreement (2022 Renewal)and the transactions contemplated thereunder.

DIRECTORS’ CONFIRMATION. The Directors (including the independent non-executive Directors) are of the view that the terms of the Promotional CMC Technical Services Framework Agreement (2022 Renewal) (including the annual cap caps thereunder) are fair and reasonable, and that the transactions contemplated under the above- mentioned agreement thereunder are in the ordinary and usual course of business of the Company, on normal commercial terms and in the interests of the Company and the Shareholders shareholders as a whole. As at the date of this announcement, as each of Xx. Xxxx Xxxx, Xx. Xxxxxx Xx, Xx. Xxxxxxx Xxxx, Xx. Xxxxx Xxxxxx Xxx and Xx. Xxxxx Xxx holds various positions with Fosun Pharma and/or their respective its subsidiaries, each of them has abstained from voting on the Board resolutions approving the Promotional CMC Technical Services Framework Agreement (2022 Renewal)and the transactions contemplated thereunder. Save for the above, to the best knowledge, information and belief of the Directors after having made all reasonable enquiries, no other Director has a material interest in the Promotional CMC Technical Services Agreement (2022 Renewal)Framework Agreement, and no other Director has abstained from voting on the relevant Board resolution resolutions approving the Promotional CMC Technical Services Framework Agreement (2022 Renewal)and the transactions contemplated thereunder.

DIRECTORS’ CONFIRMATION. The Directors (including the independent non-executive Directors) are of the view that the terms of the Promotional Clinical Trial Research Services Agreement (2022 Renewal) (including the annual cap caps thereunder) are fair and reasonable, and that the transactions contemplated under the above- mentioned agreement thereunder are in the ordinary and usual course of business of the Company, on normal commercial terms and in the interests of the Company and the Shareholders as a whole. As at the date of this announcement, as each of Xx. Xxxx Xxxx, Xx. Xxxxxx Xx, Xx. Xxxxxxx Xxxx, Xx. Xxxxx Xxxxxx Xxx and Xx. Xxxxx Xxx holds various positions with Fosun Pharma and/or their respective and/ or its subsidiaries, each of them has abstained from voting on the Board resolutions approving the Promotional Clinical Trial Research Services Agreement (2022 Renewal)and the transactions contemplated thereunder. Save for the above, to the best knowledge, information and belief of the Directors after having made all reasonable enquiries, no other Director has a material interest in the Promotional Clinical Trial Research Services Agreement (2022 Renewal)Agreement, and no other Director has abstained from voting on the relevant Board resolution resolutions approving the Promotional Clinical Trial Research Services Agreement (2022 Renewal)and the transactions contemplated thereunder.